Israel Anti-Hypertensive Drugs Market

Israel Anti-Hypertensive Drugs Market, By Therapeutic Class (Diuretics, ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others), By Type (Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores), By Region, Competition Forecast & Opportunities, 2028F

The Israel Anti-Hypertensive Drugs Market is expected to experience impressive growth during the forecast period of 2024-2028. Major contributing factors include the increasing prevalence of hypertension due to kidney diseases, diabetes, obstructive sleep apnea, and other cardiovascular diseases. This has led to a significant rise in hypertension prevalence in recent years. Furthermore, certain drugs can induce hypertension in patients with other diseases or disorders, thus fostering growth in the Israel Anti-Hypertensive Drugs market. According to the World Health Organization in 2021, approximately 1.13 billion people worldwide have hypertension, with two-thirds residing in low- and middle-income countries.

Hypertension constitutes a preventable risk factor for atherosclerotic diseases and ischemic heart diseases. Characterized by elevated blood pressure in the arteries, many patients struggle to achieve optimal blood pressure control despite the availability of modern and effective antihypertensive drugs. To prevent heart stroke, most hypertensive patients require a combination of antihypertensive agents.

Furthermore, the rise in awareness concerning hypertension complications significantly fuels the Israel anti-hypertensive drugs market's growth. The aging population and sedentary lifestyles also contribute to market expansion. However, recent patent expirations are anticipated to impede market growth, while increased research into antihypertensive drugs offers promising opportunities.

The increasing prevalence of hypertension is a significant health concern across the country. Recent data indicates that around 25% of Israel's adult population is affected by hypertension, with prevalence increasing with age. Aging population demographics contribute to this rise, as the risk of hypertension increases with age. Additionally, unhealthy lifestyle habits like high salt and saturated fat consumption, sedentary behavior, and smoking are key factors driving hypertension prevalence. Obesity, a major hypertension risk factor, is also on the rise. In response, healthcare providers emphasize early detection, treatment, and lifestyle changes. Ongoing research into effective hypertension treatments is essential in curbing its prevalence and driving demand for anti-hypertensive drugs in Israel.

Advancements in drug development are pivotal. In April 2021, Radnor Biopharma developed a hormone-based hypertension treatment. Patent expirations and side effects associated with hypertension treatments, coupled with non-pharmacological therapy availability, may restrict market growth. For example, AbbVie's patent loss for the anti-hypertensive drug Bystolic (Nebivolol) in December 2021 limits its market. Conversely, advancements like hormone targeting treatments and generic equivalents, such as Dr. Reddy's Valsartan tablets, are driving market expansion.

Government initiatives and funding, along with increased awareness, boost market growth. Israel collaborates with the United Nations to improve older persons' lives, with initiatives promoting awareness and offering health camps for blood pressure checks. Public health campaigns, educational programs, and guidelines by Israel's Ministry of Health further emphasize blood pressure management, driving awareness and treatment efforts.

In conclusion, the Israel Anti-Hypertensive Drugs Market is poised for significant growth. Factors such as rising hypertension prevalence, advancements in drug development, government initiatives, and growing awareness of health risks contribute to this expansion. Continued efforts to educate the public and implement preventive measures will likely decrease hypertension prevalence, driving further market growth.

Market Segmentation

Israel Anti-Hypertensive Drugs Market can be segmented by therapeutic class, type, distribution channel, and region. By therapeutic class, the market can be segmented into Diuretics, ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others. Based on type, the market can be segmented into Primary Hypertension and Secondary Hypertension. In terms of Distribution Channel, the market can be segmented into Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores.

Market Players

Pfizer Pharmaceuticals Israel Ltd, MERCK SERONO LTD., AstraZeneca Israel Inc, Novartis Pharma Israel Ltd, Sanofi-Aventis Israel Ltd, Boehringer Ingelheim Israel Ltd., Bristol-Myers Squibb Israel Ltd., Takeda Israel Inc., Teva Israel Ltd., Servier Israel Inc. etc. are some of the leading companies operating in the Israel anti-hypertensive drugs market.

Report Scope:

In this report, Israel Anti-Hypertensive Drugs Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Israel Anti-Hypertensive Drugs Market, By Therapeutic Class
• Diuretics
• ACE inhibitors
• Angiotensin Receptor Blockers (ARBs)
• Calcium Channel Blockers
• Beta Adrenergic Blockers
• Renin Inhibitors
• Vasodilators
• Others
• Israel Anti-Hypertensive Drugs Market, By Type
• Primary Hypertension
• Secondary Hypertension
• Israel Anti-Hypertensive Drugs Market, By Distribution Channel
• Retail Pharmacy
• Hospital Pharmacy
• E-commerce Websites
• Online Drug Stores
• Israel Anti-Hypertensive Drugs Market, By Region:
• The Mediterranean Coastal Plain
• The Central Hills
• The Jordan Rift Valley
• The Negev Desert

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Israel Anti-Hypertensive Drugs Market

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order. Single User license will be delivered in PDF format without printing rights